BRPI0516247A - métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente - Google Patents

métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente

Info

Publication number
BRPI0516247A
BRPI0516247A BRPI0516247-5A BRPI0516247A BRPI0516247A BR PI0516247 A BRPI0516247 A BR PI0516247A BR PI0516247 A BRPI0516247 A BR PI0516247A BR PI0516247 A BRPI0516247 A BR PI0516247A
Authority
BR
Brazil
Prior art keywords
treatment methods
hormonal treatment
increasing dose
period
prolonged cycle
Prior art date
Application number
BRPI0516247-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles E Diliberti
Kathleen Z Reape
Lance J Bronnenkant
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Publication of BRPI0516247A publication Critical patent/BRPI0516247A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0516247-5A 2004-10-07 2005-10-07 métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente BRPI0516247A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61642404P 2004-10-07 2004-10-07
US68456805P 2005-05-26 2005-05-26
PCT/US2005/035997 WO2006042021A2 (en) 2004-10-07 2005-10-07 Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

Publications (1)

Publication Number Publication Date
BRPI0516247A true BRPI0516247A (pt) 2008-08-26

Family

ID=36001184

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516247-5A BRPI0516247A (pt) 2004-10-07 2005-10-07 métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente

Country Status (11)

Country Link
US (1) US20060135496A1 (enExample)
EP (3) EP2392332A1 (enExample)
JP (1) JP2008515909A (enExample)
AR (1) AR051931A1 (enExample)
AU (1) AU2005294269B2 (enExample)
BR (1) BRPI0516247A (enExample)
CA (1) CA2582530A1 (enExample)
IL (1) IL182287A0 (enExample)
MX (1) MX2007004120A (enExample)
TW (1) TW200626161A (enExample)
WO (1) WO2006042021A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
NZ533242A (en) * 2001-12-05 2007-11-30 Duramed Pharmaceuticals Inc Oral extended regime contraceptive package
AU2003230321B8 (en) * 2002-05-09 2009-07-30 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
US7855190B2 (en) * 2003-07-16 2010-12-21 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
EP2343979B1 (en) 2008-10-08 2020-04-08 Agile Therapeutics, Inc. Transdermal delivery
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
EP2410859A4 (en) 2009-03-27 2013-03-13 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
WO1998004246A2 (en) * 1996-07-26 1998-02-05 American Home Prod Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
NZ533242A (en) * 2001-12-05 2007-11-30 Duramed Pharmaceuticals Inc Oral extended regime contraceptive package
US20030219471A1 (en) * 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
CA2481310A1 (en) * 2002-04-03 2003-10-16 Barr Laboratories, Inc. Step-down estrogen therapy
US7855190B2 (en) * 2003-07-16 2010-12-21 Teva Women's Health, Inc. Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US7772219B2 (en) * 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
BRPI0414945A (pt) * 2003-10-01 2006-11-07 Janssen Pharmaceutica Nv regimes contraceptivos trifásicos estendidos
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens

Also Published As

Publication number Publication date
WO2006042021A3 (en) 2006-06-08
EP1814556A2 (en) 2007-08-08
JP2008515909A (ja) 2008-05-15
US20060135496A1 (en) 2006-06-22
AU2005294269A1 (en) 2006-04-20
AU2005294269B2 (en) 2011-07-28
CA2582530A1 (en) 2006-04-20
AR051931A1 (es) 2007-02-21
EP2392332A1 (en) 2011-12-07
MX2007004120A (es) 2007-06-15
WO2006042021A2 (en) 2006-04-20
EP2392333A1 (en) 2011-12-07
IL182287A0 (en) 2008-04-13
WO2006042021B1 (en) 2006-08-03
TW200626161A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
BRPI0516247A (pt) métodos de tratamento hormonal, utilizando regimes de ciclo prolongado de dose crescente
AR047529A1 (es) Compuestos de quinolina sustituidos
NO20044699L (no) Vaginalpleiesammensetning
ATE312635T1 (de) Ventilanordnung
BR0313694A (pt) Derivados de pirazol, composição medicinal contendo os mesmos, seu uso medicinal e intermediários para sua produção
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
SE0001899D0 (sv) New compounds
EA201390332A1 (ru) Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
NO20080824L (no) Oral prevensjon med trimegeston
UY26992A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides
SE0401342D0 (sv) Therapeutic compounds
EA201400202A1 (ru) Применение эстетрола в качестве экстренного контрацептива
BR0313526A (pt) Medicamento inalativos que contêm um agente anticolinérigo, em combinação com corticoesteróides e betamiméticos
UY28945A1 (es) Derivados de pirrolopiridina
ATE516366T1 (de) Regulierte aptamer-therapeutika
BRPI0410968A (pt) combinação unitária de fsh e hcg
PL360492A1 (en) Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
MX2022009081A (es) Absorcion celular.
BR0318192A (pt) regimes contraceptivos transdérmicos prolongados
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: NOME ALTERADO DE: DURAMED PHARMACEUTICALS, INC.

B25G Requested change of headquarter approved

Owner name: TEVA WOMEN'S HEALTH, INC. (US)

Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 018110020180/SP DE 30/05/2011.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.